OINDP contract research and development company Nanopharm, a subsidiary of Aptar Pharma, has announced plans to move to a 25,000 sq ft building in Cwmbran, Wales that will house brand new R&D space and cGMP analytical labs. The new facility will be 4 times larger than the company’s existing location and will allow Nanopharm to increase its capacity to the extent that it anticipates hiring approximately 60 new employees. Construction of the new facilities is expected to be complete sometime early next year.
Nanopharm says, “Building on the company’s heritage and belief that fundamental materials science drives behavior in aerosol science, the addition of new characterization and analytical capabilities as well as increased capacity will enable Nanopharm’s scientists to provide specialist services, benefit from in-house evaluation and facilitate the customers’ desire to get to the clinic quickly, yet safely.” Those new capabilities particularly include more options for particle engineering and biologics characterization, as well as cGMP testing.
According to Nanopharm, the new R&D labs will have the flexibility to accommodate the temporary use of customer-owned equipment or other short-term set-ups in addition to the in-house capabilities, which will include a new spray dryer with the ability to scale up to commercial platforms; new micronization equipment; and a suite for handling highly potent materials, including biologics and controlled substances.
Nanopharm VP, Science & Technology, and co-founder Jag Shur said, “We are excited to take the next step in our expansion to support our customers by not only offering more services, but also having the bandwidth to work on more cutting-edge technologies to maintain our position as pioneers in the industry. This is how Nanopharm became successful from our inception, and with more people come more bright ideas, so we want to make sure we capitalize on the opportunities that the ever-changing OINDP landscape brings.”
Aptar Pharma VP, Analytical, Regulatory and Scientific Affairs, Guillaume Brouet commented, “Nanopharm continues on its exponential growth curve and has long outgrown its existing facility. This investment truly demonstrates Aptar Pharma’s commitment to supporting the growth of Nanopharm and our belief in the added value it has to offer customers as part of our diversification into offering full-service solutions.”
Read the Nanopharm press release.
